Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06666790 · ClinicalTrials.gov registry record · NA
DermaSensor Postmarket Surveillance Study
A NA study of Melanoma (Skin), sponsored by DermaSensor.
- Recruiting
- Registry status
- NA
- Development phase
- 396
- Enrollment target
- 2
- Study locations
NCT06666790 is a NA study of Melanoma (Skin) that is actively recruiting participants, run by DermaSensor. The registered enrollment target is 396 participants, above the 124-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (219% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT06666790, a NA study of Melanoma (Skin), is actively recruiting participants, sponsored by DermaSensor.
- RECRUITING
- Registry status
- NA
- Development phase
- 396 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this study is to evaluate the sensitivity of the DermaSensor device and Investigators when used on skin lesions concerning for melanoma.
Conditions Studied
Interventions
- DEVICE Scan with elastic scattering spectroscopy device to assess risk of malignancy
Study Locations (2)
Florida
- Velocity - New Smyrna Beach
North Carolina
- West Clinical Research - Morehead City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2027-09-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06666790
The ClinicalTrials.gov registry entry for NCT06666790 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 396 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 124-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (219% higher). The listed sponsor is DermaSensor, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 1 intervention - of which Scan with elastic scattering spectroscopy device to assess risk of malignancy is the first listed.
NCT06666790 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06666790 about?
NCT06666790 is a clinical study titled "DermaSensor Postmarket Surveillance Study". The objective of this study is to evaluate the sensitivity of the DermaSensor device and Investigators when used on skin lesions concerning for melanoma.
What is the current status of trial NCT06666790?
This trial is currently recruiting. It is a NA study. The enrollment target is 396 participants. The study started on 2024-10-08. Estimated completion is 2027-09-10.
What conditions does trial NCT06666790 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT06666790?
The interventions under investigation include: Scan with elastic scattering spectroscopy device to assess risk of malignancy (DEVICE).
Who is sponsoring clinical trial NCT06666790?
This trial is sponsored by DermaSensor, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06666790 being conducted?
This trial has 2 study locations across Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rural Adult and Youth Sun Protection Study
RECRUITING · NA
-
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
RECRUITING · NA
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
RECRUITING
-
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.